EnJun Yang is a seasoned researcher with significant expertise in immunology and sequencing-related projects. Currently serving as Research Director at the Parker Institute for Cancer Immunotherapy since July 2023, EnJun Yang previously held the position of Senior Research Fellow at the Institute of Molecular and Cell Biology from February 2021 to June 2023, overseeing sequencing initiatives and management of the lab's Google Cloud Platform. Prior experience includes serving as Research Scientist and Sequencing & Data Team Lead at Tessa Therapeutics Pte Ltd from September 2018 to January 2021, as well as a Postdoctoral Fellow at the Genome Institute of Singapore from March 2016 to August 2018. Educational qualifications consist of a Doctor of Philosophy (PhD) in Immunology from the University of Pennsylvania, obtained in 2016, and a Bachelor of Science in Biology from the University of Michigan, completed in 2009.
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.